Rubric Capital Management Sells 25,000 Collegium Pharmaceutical Shares for $946,250

Rubric Capital Management LP sold 25,000 Collegium Pharmaceutical shares worth $946,250 on August 15, 2025. The company reported record Q2 2025 earnings with a 29% YoY net revenue increase to $188 million. Collegium raised its full-year 2025 revenue guidance to $745-$760 million and adjusted EBITDA guidance to $440-$455 million. The company also announced a $150 million share repurchase program. Despite GAAP net income decline, the overall business outlook remains optimistic.

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has seen significant insider activity and reported strong Q2 2025 earnings. On August 15, 2025, Rubicon Capital Management LP sold 25,000 shares of Collegium Pharmaceutical, worth $946,250 [1]. This sale comes amidst a period of robust financial performance for the company.

Collegium Pharmaceutical reported record Q2 2025 earnings with a 29% year-over-year (YoY) net revenue increase to $188 million. The company raised its full-year 2025 revenue guidance to $745-$760 million and adjusted EBITDA guidance to $440-$455 million. Despite a GAAP net income decline, the overall business outlook remains optimistic, with the company announcing a $150 million share repurchase program [2].

The insider selling by Rubicon Capital Management LP could be interpreted as a response to the recent earnings report. However, it is essential to consider this activity within the broader context of the company's financial health. Collegium Pharmaceutical's strong revenue growth and positive outlook suggest that the company is well-positioned to continue its growth trajectory.

Collegium Pharmaceutical's recent stock performance has been mixed, with the stock trading up $0.58 on Friday, August 8, 2025, hitting $37.74. The company's debt-to-equity ratio stands at 3.27, and its current ratio is 1.18, indicating a relatively healthy financial position. The firm's 50-day moving average price is $31.54, and its 200-day moving average price is $29.80. Analysts have been upgrading the stock, with HC Wainwright and Wall Street Zen both upgrading Collegium Pharmaceutical to a "strong-buy" rating [1].

In summary, Collegium Pharmaceutical's Q2 2025 earnings report and insider selling activity provide a mixed picture. While the company's financial performance is strong, the insider selling suggests that some investors are taking profits or adjusting their positions. However, the overall business outlook remains optimistic, and the company's share repurchase program could be seen as a vote of confidence from management.

References:
[1] https://www.marketbeat.com/instant-alerts/insider-selling-collegium-pharmaceutical-inc-nasdaqcoll-director-sells-11659-shares-of-stock-2025-08-12/
[2] https://www.benzinga.com/insights/news/25/08/47094471/director-of-collegium-pharmaceutical-sold-400k-in-stock